Navigation Links
The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan
Date:11/14/2011

NEW YORK, Nov. 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title='The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country'>The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country

http://www.reportlinker.com/p0365376/The-2011-Prostatic-Acid-Phosphatase-Testing-Market-US-Europe-Japan

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

This report presents a detailed analysis of the PAP testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 242 pages and 11 tables

Table of Contents

I. Introduction

II. Worldwide Market and Technology Overview

A. Prostatic Acid Phosphatase: Clinical Significance

and Laboratory Practices

B. Instrumentation Review And

Market Needs

1. Abbott AxSYM

2. Abbott IMx

3. Anagen AN2000/AuraFlex

4. Beckman Coulter Access

5. BioChem Pharma SR1

6. bioMerieux Vidas Series

7. Biotrol Systems 7000

8. J&J Diagnostics/Amersham Amerlite

9. J&J Diagnostics Vitros ECI

10. Olympus PK Series

11. Roche Cobas Core

12. Roche Elecsys

13. Roche ES 22

14. Roche ES 33

15. Roche ES 300/300 AL

16. Siemens ACS: 180

17. Siemens ACS: Centaur

18. Siemens ELISA Processor II/III

19. Siemens Immuno 1

20. Siemens/Opus/Plus/Magnum

21. Siemens Stratus

22. Tosoh AIA Series

23. Wallac/Pharmacia Delfia

C. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

Particle-Membrane Capture Immunoassay

Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

Chemiluminescence

Bioluminescence

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

PCR

DAP-PCR

Immuno-PCR

QC-PCR

CAR

DNA

HPA

LCR

NASBA

QBR

SDA

3 SR, and others

4. Biochips/Microarrays

5. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

6. Microcomputers and Automation

7. Artificial Intelligence

8. Flow Cytometry

9. Biosensors

D. Competing/Complementing Technologies

1. CT

2. MRI

3. NMR

4. PET

5.Photonics Spectroscopy

E. Personal Testing

III. France: Market Size, Growth and Major Suppliers' Sales and Market Shares

IV. Germany: Test Volume and Diagnostics Sales Forecast by Market Segment

V. Italy: Test Volume and Diagnostics Sales Forecast by Market Segment

VI. Japan: Market Size, Growth and Major Suppliers' Sales and Market Shares

VII. Spain: Test Volume and Diagnostics Sales Forecast by Market Segment

VIII. U.K.: Test Volume and Diagnostics Sales Forecast by Market Segment

IX. U.S.A.: Market Size, Growth and Major Suppliers' Sales and Market Shares

X. Design Criteria for Decentralized Testing Products

XI. Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

XII. Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

XIII. Competitive Profiles

Abbott

AdnaGen

Ambrilia Biopharma

AMDL

Beckman Coulter

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CanAG Diagnostics

CeMines

Cepheid

Correlogic Systems

Dako

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Gen-Probe

Guided Therapeutics

Hologic

Ipsogen

J&J Diagnostics

Kreatech

Kyowa Medex

Mackay Life Sciences

Matritech

Myriad Genetics

OncoLab

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Veridex

Wako Pure Chemicals

Wallac

Zila

List of Tables

Major Companies Developing or Marketing PAP Tests

France

PAP Test Volume and Diagnostics Sales by Market Segment

France

PAP Testing Market by Major Supplier

Germany

PAP Test Volume and Diagnostics Sales by Market Segment

Italy

PAP Test Volume and Diagnostics Sales by Market Segment

Japan

PAP Test Volume and Diagnostics Sales by Market Segment

Japan

PAP Testing Market by Major Supplier

Spain

PAP Test Volume and Diagnostics Sales by Market Segment

U.K.

PAP Test Volume and Diagnostics Sales by Market Segment

U.S.A.

PAP Test Volume and Diagnostics Sales by Market Segment

U.S.A.

PAP Testing Market by Major Supplier

To order this report:

:

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title='The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country'>The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country

More  Market Research Report

Check our  Real Time Industry Data

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
2. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
3. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
4. AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure
5. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
6. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
7. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
8. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
9. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
10. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
11. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):